Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20401477 | 0.71 | HSD17B1 (0.48) | — | |
| SCHEMBL12550527 | 0.69 | ALDH1A1 (0.48) | OXTR | |
| SCHEMBL16872766 | 0.69 | AKT2 (0.95) | ROCK2AKT1AKT2 | |
| SCHEMBL3250449 | 0.68 | ROCK2 (0.56) | ROCK2AKT1AKT2ROCK1 | |
| SCHEMBL21025333 | 0.68 | ROCK1 (0.49) | ROCK2AKT1AKT2ROCK1 | |
| SCHEMBL14134390 | 0.67 | POLB (0.57) | — | |
| SCHEMBL14134508 | 0.67 | POLB (0.57) | — | |
| SCHEMBL14134499 | 0.67 | POLB (0.57) | — | |
| SCHEMBL82741 | 0.67 | AKT2 (1.00) | ROCK2AKT1AKT2 | |
| Benzene SCHEMBL28198087 | 0.67 | AKT2 (1.00) | ROCK2AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ROCK2 400/4885AKT1 514/4885AKT2 476/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ROCK2 400/4885AKT1 514/4885AKT2 476/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ROCK2 400/4885AKT1 514/4885AKT2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.